Cencora, Inc. (NYSE:COR) Stock Holdings Decreased by Voya Financial Advisors Inc.

Voya Financial Advisors Inc. decreased its stake in shares of Cencora, Inc. (NYSE:COR) by 2.3% during the 4th quarter, according to its most recent Form 13F filing with the SEC. The fund owned 7,612 shares of the company’s stock after selling 176 shares during the period. Voya Financial Advisors Inc.’s holdings in Cencora were worth $1,710,000 as of its most recent filing with the SEC.

Several other hedge funds and other institutional investors have also recently bought and sold shares of COR. Passumpsic Savings Bank lifted its stake in Cencora by 4.9% during the third quarter. Passumpsic Savings Bank now owns 6,464 shares of the company’s stock worth $1,455,000 after purchasing an additional 304 shares during the last quarter. Virtu Financial LLC raised its holdings in shares of Cencora by 112.2% during the third quarter. Virtu Financial LLC now owns 10,227 shares of the company’s stock worth $2,302,000 after purchasing an additional 5,407 shares during the period. World Investment Advisors LLC bought a new position in shares of Cencora in the 3rd quarter worth about $4,072,000. Arvest Bank Trust Division acquired a new position in shares of Cencora in the 3rd quarter valued at about $218,000. Finally, Wilmington Savings Fund Society FSB bought a new stake in shares of Cencora during the 3rd quarter valued at about $566,000. 97.52% of the stock is owned by institutional investors.

Cencora Stock Performance

NYSE:COR opened at $281.89 on Friday. The company has a 50-day moving average of $267.20 and a 200-day moving average of $248.71. The firm has a market cap of $54.66 billion, a price-to-earnings ratio of 40.10, a price-to-earnings-growth ratio of 1.31 and a beta of 0.55. The company has a current ratio of 0.92, a quick ratio of 0.54 and a debt-to-equity ratio of 16.40. Cencora, Inc. has a twelve month low of $214.77 and a twelve month high of $296.65.

Cencora (NYSE:COR) last posted its quarterly earnings results on Wednesday, February 5th. The company reported $3.73 earnings per share (EPS) for the quarter, topping the consensus estimate of $3.50 by $0.23. Cencora had a net margin of 0.46% and a return on equity of 328.62%. Analysts forecast that Cencora, Inc. will post 15.37 earnings per share for the current fiscal year.

Cencora Dividend Announcement

The business also recently declared a quarterly dividend, which was paid on Monday, March 3rd. Investors of record on Friday, February 14th were given a $0.55 dividend. The ex-dividend date of this dividend was Friday, February 14th. This represents a $2.20 dividend on an annualized basis and a dividend yield of 0.78%. Cencora’s dividend payout ratio (DPR) is 31.29%.

Insider Buying and Selling

In other Cencora news, EVP Elizabeth S. Campbell sold 4,127 shares of the business’s stock in a transaction on Monday, March 24th. The shares were sold at an average price of $268.28, for a total transaction of $1,107,191.56. Following the sale, the executive vice president now directly owns 14,665 shares of the company’s stock, valued at $3,934,326.20. The trade was a 21.96 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. Also, EVP Silvana Battaglia sold 5,000 shares of Cencora stock in a transaction on Friday, February 21st. The shares were sold at an average price of $242.24, for a total value of $1,211,200.00. Following the transaction, the executive vice president now owns 15,374 shares in the company, valued at $3,724,197.76. This represents a 24.54 % decrease in their position. The disclosure for this sale can be found here. In the last quarter, insiders have sold 50,223 shares of company stock valued at $13,580,967. 10.80% of the stock is owned by corporate insiders.

Wall Street Analyst Weigh In

A number of brokerages have commented on COR. Wells Fargo & Company lifted their target price on Cencora from $251.00 to $274.00 and gave the company an “equal weight” rating in a research note on Friday, March 14th. StockNews.com upgraded Cencora from a “hold” rating to a “buy” rating in a research note on Wednesday, March 12th. Evercore ISI boosted their price target on shares of Cencora from $270.00 to $280.00 and gave the company an “outperform” rating in a report on Thursday, February 6th. JPMorgan Chase & Co. increased their price objective on shares of Cencora from $289.00 to $301.00 and gave the stock an “overweight” rating in a report on Friday, January 24th. Finally, Bank of America boosted their target price on shares of Cencora from $270.00 to $285.00 and gave the company a “neutral” rating in a research note on Friday, April 11th. Two analysts have rated the stock with a hold rating and nine have assigned a buy rating to the company’s stock. According to data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and an average price target of $284.55.

Cencora Profile

Cencora, Inc sources and distributes pharmaceutical products. The company's U.S. Healthcare Solutions segment distributes pharmaceuticals, over-the-counter healthcare products, home healthcare supplies and equipment, and related services to acute care hospitals and health systems, independent and chain retail pharmacies, mail order pharmacies, medical clinics, long-term care and alternate site pharmacies, and other customers; provides pharmacy management, staffing, and other consulting services; supply management software to retail and institutional healthcare providers; packaging solutions to various institutional and retail healthcare providers; clinical trial support, product post-approval, and commercialization support services; data analytics, outcomes research, and additional services for biotechnology and pharmaceutical manufacturers; pharmaceuticals, vaccines, parasiticides, diagnostics, micro feed ingredients, and other products to the companion animal and production animal markets; and sales force services to manufacturers.